Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
BMC Cancer
|
April 16, 2020
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
Wei Fang Dai, Jaclyn M Beca, Ruth Croxford, et al.
JAMA Network Open
|
November 15, 2021
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
Michael J Raphael, William Raskin, Steven Habbous, et al.
MDM Policy & Practice
|
July 2, 2021
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
Reka E Pataky, Jaclyn Beca, David Tran, et al.
International Journal of Cancer
|
October 26, 2020
Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada
Wei Fang Dai, Jaclyn Beca, Ruth Croxford, et al.
Leukemia & Lymphoma
|
December 6, 2018
Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent
James K R Stevenson, Yao Qiao, Kelvin K W Chan, et al.
CMAJ Open
|
June 10, 2016
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study
Nicolas J Chin-Yee, Andrew T Yan, Alexander Kumachev, et al.
International Journal of Technology Assessment in Health Care
|
August 12, 2020
Impact of rarity on Canadian oncology health technology assessment and funding
James Keech, Wei Fang Dai, Maureen Trudeau, et al.
Cancer Medicine
|
March 31, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization
Brandon Lu, Wei Fang Dai, Ruth Croxford, et al.
BMC Cancer
|
August 14, 2014
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
Sara Khor, Jaclyn Beca, Murray Krahn, et al.
JNCI Cancer Spectrum
|
June 27, 2022
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
Vanessa Arciero, Jin Luo, Ambica Parmar, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
BMC Cancer
|
April 16, 2020
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
Wei Fang Dai, Jaclyn M Beca, Ruth Croxford, et al.
JAMA Network Open
|
November 15, 2021
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer
Michael J Raphael, William Raskin, Steven Habbous, et al.
MDM Policy & Practice
|
July 2, 2021
Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
Reka E Pataky, Jaclyn Beca, David Tran, et al.
International Journal of Cancer
|
October 26, 2020
Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada
Wei Fang Dai, Jaclyn Beca, Ruth Croxford, et al.
Leukemia & Lymphoma
|
December 6, 2018
Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent
James K R Stevenson, Yao Qiao, Kelvin K W Chan, et al.
CMAJ Open
|
June 10, 2016
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study
Nicolas J Chin-Yee, Andrew T Yan, Alexander Kumachev, et al.
International Journal of Technology Assessment in Health Care
|
August 12, 2020
Impact of rarity on Canadian oncology health technology assessment and funding
James Keech, Wei Fang Dai, Maureen Trudeau, et al.
Cancer Medicine
|
March 31, 2023
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization
Brandon Lu, Wei Fang Dai, Ruth Croxford, et al.
BMC Cancer
|
August 14, 2014
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
Sara Khor, Jaclyn Beca, Murray Krahn, et al.
JNCI Cancer Spectrum
|
June 27, 2022
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
Vanessa Arciero, Jin Luo, Ambica Parmar, et al.
Page
of 3